Previous close | 3.1850 |
Open | 3.2000 |
Bid | 3.2500 x 400 |
Ask | 3.2900 x 400 |
Day's range | 3.1700 - 3.3700 |
52-week range | 1.3700 - 9.8000 |
Volume | |
Avg. volume | 864,558 |
Market cap | 172.314M |
Beta (5Y monthly) | 2.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript March 28, 2024 Kodiak Sciences Inc. misses on earnings expectations. Reported EPS is $-1.13 EPS, expectations were $-0.86. Kodiak Sciences Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]